Nature Communications (Nov 2022)
DNA barcoding reveals ongoing immunoediting of clonal cancer populations during metastatic progression and immunotherapy response
Abstract
Understanding the molecular mechanisms of cancer immunoediting could provide insight into resistance to immunotherapy. Here, DNA barcoding provides evidence of ongoing immunoediting during metastasis and treatment with anti-PD1 and anti-CTLA4, and identifies cancer cell clones with unique immune evasive phenotypes.